Loyens & Loeff is pleased to announce the Food Law Classes, a unique training programme developed by its Food & Beverages team.
In 10 monthly classes you will receive in-depth and up-to-date knowledge of EU, Belgian, Dutch and Luxembourg food law as well as other legal and tax matters that impact the food sector. Each class will last half a day and will focus on the theoretical framework and its practical application.
The programme is prepared and presented by members of the Loyens & Loeff Food & Beverages team as well as by high profile external speakers.
21/09/2017 - Risks, Liabilities and Sanctions
19/10/2017 - Mandatory Food Information
16/11/2017 - Voluntary Food Information
14/12/2017 - Nutrition and Health Claims
25/01/2018 - Intellectual Property Rights and Trade Secrets
22/02/2018 - International Trade
22/03/2018 - Competition Issues
26/04/2018 - Food Law in the Day-to-Day Business
24/05/2018 - Food Governance and EU Procedure
21/06/2018 - Data Protection Issues
Where: Loyens & Loeff Brussels or by webinar
When: from 13.30 till 17.30
Lexology has launched a new series of webinars focusing on hot legal issues worldwide. We are delighted to partner with leading Swiss law firm Bär & Karrer to give in-house counsel and private practice lawyers worldwide a clear, practical understanding of the current position of Arbitration in Switzerland, as well as focusing on evolving trends.
Switzerland has been, for quite some time now, one of the most important places for international arbitration in Europe. The yearly statistics of the ICC in Paris lists Swiss venues such as Geneva and Zurich as having among the highest frequency of chosen seats for arbitrations, trailing only Paris and London. Swiss arbitrators, directly behind their British and US equivalents, are among those consistently chosen to sit on arbitration panels. Moreover, the leading Swiss arbitration body, the Swiss Chambers' Arbitration Institution, annually posts around 100 new cases.
Nevertheless, the world of arbitration is developing quickly, as are the requirements for an attractive and effective arbitration site. Daniel Hochstrasser, Pierre-Yves Gunter and Nadja Jaisli, three leading Swiss arbitration specialists at Bär & Karrer, explain the current state of play, and provide you with their insight and outlook for the future.
Pierre-Yves Gunter, Partner, Bär & Karrer
Pierre-Yves has been acting in international arbitration for 27 years as counsel and arbitrator in particular in matters involving infrastructure/construction, post M&A, licensing, sales, distribution, TMT, pharmaceutical and energy (oil & gas) disputes.
Daniel Hochstrasser, Partner, Bär & Karrer
Daniel focuses on representing parties in complex disputes arising from M&A transactions, industrial and infrastructure projects, banking and finance, as well as license agreements, particularly in the pharmaceutical field. Since July 2015, he is a member of the ICC Court of Arbitration, Paris.
Nadja Jaisli Kull, Partner, Bär & Karrer
Nadja is specialized in representing clients in international arbitrations and before Swiss courts, and also sits as arbitrator (in particular under ICC, Swiss and DIS Rules). Since 2017, she is a board member of the Swiss Arbitration Association (ASA).
About Bär & Karrer:
Bär & Karrer is a renowned Swiss law firm with more than 150 lawyers in Zurich, Geneva, Lugano and Zug. The firm’s core business is advising clients on innovative and complex transactions and representing them in litigation, arbitration and regulatory proceedings. Clients range from multinational corporations to private individuals in Switzerland and around the world.
Litigation finance – a transformative financial tool with benefits for in-house legal teams and law firms – grew more than four-fold between 2013 and 2017. This webinar will provide insights into what’s driving that growth, and shed light on how in-house teams can use financing to shift cost and risk off balance sheets and improve accounting outcomes without sacrificing the pursuit or defense of claims with value to the business. Travis Lenkner of Burford Capital, the world’s largest provider of litigation finance, will define the types of legal financing products available, explain the timing and process for securing financing, and address ethical considerations as well as what to look for in a financing partner.
Managing Director, Burford Capital
Travis Lenkner is a Managing Director of Burford Capital. Mr. Lenkner co-founded Gerchen Keller Capital and as Managing Director helped steer its growth to $1.3 billion in assets under management prior to its acquisition by Burford. His experience includes roles as in-house counsel at a Fortune 50 company, a litigator at one of the world’s leading law firms and a law clerk at the Supreme Court of the United States.
Prior to helping launch Gerchen Keller in 2013, Mr. Lenkner was a Senior Counsel at The Boeing Company, the world’s largest aerospace firm and the leading manufacturer of commercial jetliners and defense, space and security systems. While at Boeing, he represented the company in litigation matters and advised senior executives on significant regulatory issues.
Previously, Mr. Lenkner was a litigation and appellate attorney in the New York and Washington offices of Gibson, Dunn & Crutcher LLP, where he represented clients in complex civil and criminal disputes before the Supreme Court and other tribunals.
The Aspens on Blackcomb, Whistler, Canada.
A unique professional development opportunity for lawyers, accountants, directors and business advisors, the Australian Professional Advisors Conference (APAC) is an opportunity to combine professional education, networking, skiing and a family holiday over an unforgettable 7 days.
For APAC 2018 we are thrilled to be visiting Whistler, Canada for 13- 20January 2016. We invite you to join us to build relationships with other professionals and to share expert knowledge and perspectives in a family friendly atmosphere. APAC is the ultimate opportunity to combine professional development with daily group skiing, dinners and even special activities for the kids!
The exceptional Aspens on Blackcomb is nestled slope-side on Blackcomb Mountain in Whistler for the ultimate ski-in/ski-out convenience. With spectacular views, year-round heated outdoor pool and hot tubs are a welcome venue after a hard day on the slopes. With a great mix of terrain, from cruising, to bumps and trees, we can promise that if you have not been to Whistler before, you will fall in love with it. There truly is something for everyone. Click here to check out the Aspens on Blackcomb brochure.
Aspens on Blackcomb is easily accessible via direct flights to Vancouver and a connecting flight to Kamloops. We can assist you in organising all your travel needs.
European pharmaceutical and medical devices companies operate in an environment which is heavily regulated at the EU level. The complexity of this EU regulatory environment is ever increasing and the Court of Justice of the European Union (ECJ), Europe’s highest court, plays an important role in the interpretation and application of these rules.
In this webinar, two life sciences regulatory experts will guide you through the ECJ’s latest judgments in the field, which span topics as diverse as, for instance, data exclusivity, liability for defective products and parallel trade, and provide practical tips for your business. The speakers will also update you on the key cases to watch in 2018. This webinar is a must for everyone involved in life sciences regulatory affairs.
Catherine Longeval specialises in litigation before the Belgian and EU courts and advises clients on a wide range of issues, including life sciences law. Her expertise in this area covers laws governing medicines, biotech products, medical devices, cosmetics and food supplements, among other aspects.
Catherine began her professional career in October 1989. Prior to joining Van Bael & Bellis in 1994, she worked as an associate with a leading Brussels law firm.
She regularly lectures and writes on life sciences regulatory matters and procedural law matters. She often speaks at conferences.
Koen specialises in dispute resolution with a focus on the life sciences sector (medicines and medical devices). In addition to his contentious work, Koen advises life sciences clients on Belgian and EU regulatory matters. His expertise covers a wide range of areas, including clinical trials, marketing authorisations, reimbursement matters, advertising and promotion, distribution issues and aspects of competition law.
Notable experience includes: assisting a prominent medical devices company in a dispute with the Federal Agency for Medicines and Health Products in relation to the classification and distribution of certain of its products; representing a major pharmaceutical company in proceedings before the Committee for Deontology and Ethics in the Pharmaceutical Industry of pharma.be; and representing a number of pharmaceutical companies in civil and administrative proceedings initiated by a parallel trader.
17 January 2018
8.15am - 11am
Adelaide House, London Bridge
We are delighted to invite you to join our annual seminar on financial regulation. This year we will be focussing on the challenges of adjusting to the increasing pace of regulatory change, as regulators seek to keep up with the speed of information innovation.
Why should you attend?
At this seminar we will discuss the key regulatory developments that lie ahead in 2018, spanning MiFID II, Brexit, financial crime and other important areas.
The seminar will then split into sector-focussed breakout sessions to give you the opportunity to explore the main developments relevant to your particular area in greater detail with members of our regulatory team.
Who should attend?
Senior legal, risk, compliance and regulatory professionals from UK-based banks, insurers and asset managers.
The growing number of Phase II reviews and conditional approval decisions in recent years signals that the Turkish Competition Board is inclined to go into Phase II review and seek commitments if it finds a transaction causes potential competition law concerns. This indicates that remedies and conditional clearances are becoming increasingly important under the Turkish merger control regime.
During this webinar, Mr. Gönenç Gürkaynak, the managing partner of ELIG, Attorneys-at-Law, will introduce you to the remedies and Phase II reviews under the Turkish merger control regime.
The webinar will include discussions on:
The webinar will also feature recent merger decisions from Turkey with a specific focus on transactions taken into Phase II review.
Mr. Gönenç Gürkaynak is a founding partner and the managing partner of ELIG, Attorneys-at-Law, a leading law firm of 87 lawyers based in Istanbul, Turkey. Mr. Gürkaynak graduated from Ankara University, Faculty of Law in 1997, and was called to the Istanbul Bar in 1998. Mr. Gürkaynak received his LL.M. degree from Harvard Law School, and is qualified to practice in Istanbul, New York, Brussels and England and Wales (currently a non-practising Solicitor). Before founding ELIG, Attorneys-at-Law in 2005, he worked as an attorney at the Istanbul, New York and Brussels offices of a global law firm for more than eight years.
Mr. Gürkaynak heads the competition law and regulatory department of ELIG, Attorneys-at-Law, which currently consists of 45 lawyers. He has unparalleled experience in Turkish competition law counseling issues with more than 20 years of competition law experience, starting with the establishment of the Turkish Competition Authority. Every year Mr. Gürkaynak represents multinational companies and large domestic clients in more than 20 written and oral defences in investigations of the Turkish Competition Authority, about 15 antitrust appeal cases in the high administrative court, and over 60 merger clearances of the Turkish Competition Authority, in addition to coordinating various worldwide merger notifications, drafting non-compete agreements and clauses, and preparing hundreds of legal memoranda concerning a wide array of Turkish and EC competition law topics.
Marketing a generic or alternative pharmaceutical product has always necessitated an analysis of (most commonly further generation) patents that may stand in the way of a successful launch. But what to do once potential roadblocks have been identified? In the UK, it has long been accepted that generics should ‘clear the way’ to avoid a preliminary injunction (PI). The Dutch approach has traditionally been quite different: PI proceedings take the form of a ‘mini-trial’ on the merits of both infringement and validity of the patent(s) in issue. Recently, however, there has been some movement in the case law of the Patents Court. In this webinar Koen Bi-jvank and Jan Pot discuss these developments and what they mean in terms of litigation strate-gies for both patentees and generics.
Koen Bijvank is a Dutch and European patent attorney (admitted in 1998 and 1999, respectively). He specializes in international patent litigation and regularly appears both in the courts and before the European Patent Office. His practice mainly involves patents in the areas of chemistry, pharmaceuticals and life sciences.
Clients and legal directories say about Koen: “He is extremely creative and always manages to find solutions. Technically gifted, extremely knowledgeable and at the top of his game, he is someone you can be confident in in a courtroom setting.” and “He has a very practical focus that is aligned with business perspectives in situations; he’s not just an academic or a lawyer just giving you lawyer spiel.”
IAM Patents 1000: “Brinkhof has further boosted its contentious capabilities with the recent addition of chemistry and life sciences ace Koen Bijvank; the former V O Patents & Trademark man is a veteran in opposition proceedings before national courts and the EPO.”
Jan Pot (admitted to the bar in 2013) is specialized in patent law. He mainly litigates complex national and international patent disputes in front of the Dutch Courts, and has represented clients in both first instance and on appeal, as well as before the Supreme Court of the Netherlands. He also has experience representing clients in opposition and appeal proceedings at the European Patent Office.
Jan regularly publishes in IP journals and is one of the authors of the loose leaf commentary on the Dutch Patent Act. He is recognized in the 2017 Managing IP - IP Stars, alongside fellow litigator Mark van Gardingen, as "[an] extremely talented individual who [is] excellent at putting together your case in the best possible light".
Before joining Brinkhof in January 2013 and being called to the bar, Jan clerked at the District Court of Amsterdam for several years.
The Oxford Belfry Hotel, Oxfordshire
The UK's largest and only event delivering technology strategy to in-house legal teams.
Once again, Ascertus is co-sponsoring The Alternative In-house Technology Summit 2018, the UK’s only event focussed on delivering technology strategy to in-house legal teams. Aimed at technology leaders in corporate legal, the event will offer insight into the latest developments that will impact the legal, in-house legal, accountancy and consultancy sectors alongside practical take-aways on what departments can do to overcome their business challenges.
You will hear from innovative legal business and technology industry leaders on wide-ranging topics including everything from emerging technology and legislations and regulations through to successful technology and business case studies.
Who is this event for?
The programme has been developed just for in-house legal, with your resources and constraints in mind. You’ll meet the ‘right’ people in an informal and intimate environment. There will also be ample time for interaction, knowledge sharing and networking with other like-minded in-house counsel and legal teams, who are facing the same challenges as you, in planning for tomorrow.
What is “alternative” about this event?
There is a varied and entertaining mix of plenaries, panels, discussion groups, interactive think-tank, masterclasses and topic experts.
No fewer than 18 facilitated round table discussions provide insight into your peers’ challenges, and help you find solutions to your own. The “Chatham House rules” format gives you the freedom to speak your mind. The small groups by design allow everyone to participate and each group feeds back, giving all attendees access to the knowledge pool.
This year, Ascertus will be hosting a case study round table session with Carillon Plc to explore how to influence departmental culture, secure lawyer buy-in for new technology adoption and make the new way of working successful.
Lexology clients have been allocated a limited number of complimentary passes. If you are interested in attending this event, register using the code ASCERTUS.
Last year’s Brexit vote added further uncertainty to an already precarious life sciences IP market. And, with the Unified Patent Court now thrown into confusion, the political and legislative landscape is one to navigate with caution.
Against this backdrop, the second annual Pharma and Biotech IP Summit will once again bring together leading IP experts from across life sciences. Attendees will hear the latest IP strategies for thriving at a time when regulatory and legislative changes are significantly impacting business models.
How will you benefit from attending Pharma and Biotech IP Summit 2017?
Plus meet with senior decision makers and experts from across the industry during four hours of dedicated networking opportunities.
The Pharma and Biotech IP Summit 2017 has been submitted for approval for CPD hours. Subject to this approval, the projected CPD credits awarded could be up to 5.5 hours.